We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+54.86%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$1.56B
AUM Growth
+$837M
Cap. Flow
+$618M
Cap. Flow %
39.64%
Top 10 Hldgs %
44.99%
Holding
85
New
33
Increased
20
Reduced
4
Closed
28
Avg Time Held Equity + Options
0.2 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.1 years
Avg Time Held Equity only
0.2 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.1 years

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$94.1M
2
BAX icon
Baxter International
BAX
+$69.8M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$46.6M
4
ARVN icon
Arvinas
ARVN
+$45.7M
5
IMMU
Immunomedics Inc
IMMU
+$41.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$49.1M
2
MRK icon
Merck
MRK
+$37.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$25.5M
4
CAH icon
Cardinal Health
CAH
+$24.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.67%
2 Miscellaneous 1.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ABBV icon
1
AbbVie
ABBV
$501B
$152M 9.72%
1,545,400
+1,068,400
+224% +$94.1M
2019 Q4
2 quarters
REGN icon
2
Regeneron Pharmaceuticals
REGN
$82B
$82.4M 5.28%
132,100
+82,100
+164% +$46.6M
2020 Q1
1 quarter
BHVN icon
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$80.8M 5.18%
1,104,500
+564,500
+105% +$30M
2020 Q1
1 quarter
BAX icon
4
Baxter International
BAX
$13.3B
$69M 4.42%
+800,900
New +$69.8M
2020 Q2
0 quarters
IMMU
5
DELISTED
Immunomedics Inc
IMMU
$67.7M 4.34%
1,911,300
+1,418,300
+288% +$41.5M
2019 Q4
2 quarters
EXEL icon
6
Exelixis
EXEL
$15.6B
$64M 4.1%
2,694,070
+1,608,070
+148% +$37.3M
2020 Q1
1 quarter
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$57M 3.65%
507,700
+347,700
+217% +$36.9M
2020 Q1
1 quarter
HOLX icon
8
DELISTED
Hologic
HOLX
$46.6M 2.99%
+817,200
New +$40.1M
2020 Q2
0 quarters
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$42.6M 2.73%
250,900
-329,100
-57% -$49.1M
2020 Q1
1 quarter
AUPH icon
10
Aurinia Pharmaceuticals
AUPH
$2.23B
$40.2M 2.58%
2,474,599
+1,292,599
+109% +$20.7M
2019 Q4
2 quarters
MNTA
11
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$38.3M 2.45%
1,150,000
+370,000
+47% +$11.8M
2019 Q4
2 quarters
CCXI icon
12
DELISTED
ChemoCentryx, Inc.
CCXI
$37.2M 2.38%
645,800
+409,800
+174% +$22.3M
2020 Q1
1 quarter
ARVN icon
13
Arvinas
ARVN
$468M
$36.1M 2.32%
+1,076,900
New +$45.7M
2020 Q2
0 quarters
AXSM icon
14
Axsome Therapeutics
AXSM
$8.47B
$33.3M 2.14%
404,900
+207,900
+106% +$16M
2020 Q1
1 quarter
KDMN
15
DELISTED
Kadmon Holdings, Inc.
KDMN
$32.9M 2.11%
6,426,700
+3,598,700
+127% +$16.1M
2019 Q4
2 quarters
PRNB
16
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$32.8M 2.1%
+548,500
New +$33.9M
2020 Q2
0 quarters
ZNTL icon
17
Zentalis Pharmaceuticals
ZNTL
$212M
$32.4M 2.08%
+674,487
New +$25.9M
2020 Q2
0 quarters
HZNP
18
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$29.8M 1.91%
536,200
+203,200
+61% +$8.69M
2019 Q4
2 quarters
ESPR icon
19
DELISTED
Esperion Therapeutics
ESPR
$28.7M 1.84%
559,700
+354,700
+173% +$14.8M
2019 Q4
2 quarters
AVTR icon
20
Avantor
AVTR
$10.9B
$27.4M 1.76%
+1,612,000
New +$26.2M
2020 Q2
0 quarters
VIR icon
21
Vir Biotechnology
VIR
$1.77B
$25.4M 1.63%
+620,600
New +$20.8M
2020 Q2
0 quarters
MRSN icon
22
DELISTED
Mersana Therapeutics
MRSN
$25M 1.6%
+42,784
New +$14.6M
2020 Q2
0 quarters
DVAX icon
23
DELISTED
Dynavax Technologies
DVAX
$23.7M 1.52%
2,674,154
-1,149,846
-30% -$5.81M
2019 Q4
2 quarters
SNDX icon
24
Syndax Pharmaceuticals
SNDX
$1.22B
$22.6M 1.45%
+1,527,400
New +$23.3M
2020 Q2
0 quarters
NBIX icon
25
Neurocrine Biosciences
NBIX
$13.9B
$22.6M 1.45%
185,100
+87,100
+89% +$9.63M
2019 Q4
2 quarters
1
2 3 4

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Avidity Partners Management's Q2 2020 Portfolio in Review

As of Q2 2020, Avidity Partners Management held 85 positions worth $1.56B, up 116% from $724M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Avidity Partners Management deployed $618M of net new capital in Q2 2020, opening 33 new positions and adding to 20 existing holdings. Its largest new stake was Baxter International: 800,900 shares worth $69M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $49.1M trimmed.

  • Avidity Partners Management's largest Q2 2020 buy was Baxter International: 800,900 shares worth $69M.
  • Avidity Partners Management added most to AbbVie in Q2 2020, an estimated $94.1M increase.
  • Avidity Partners Management's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $49.1M.
  • Avidity Partners Management fully exited Merck in Q2 2020, selling an estimated $37.9M.
  • Avidity Partners Management's ten largest holdings make up 45% of its $1.56B portfolio in Q2 2020.
  • Avidity Partners Management opened 33 new positions and closed 28 in Q2 2020.
  • Avidity Partners Management's portfolio value rose 116% quarter-over-quarter to $1.56B.

Based on Avidity Partners Management's 13F filing for Q2 2020, filed 14 Aug 2020.